No profile data available.
Nascent Biotech, Inc. (NBIO) is a healthcare company in the additional cancer treatment drugs industry, based in North Palm Beach, United States.
It reported revenue of $0 for fiscal year 2024, and net income of -$2.09 million. In Q1 2025 (the quarter ended June 30, 2024) revenue was $0. Its market capitalization was $34,443 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2024; market data as of October 8, 2026.
, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Nascent Biotech reported $0 in revenue for fiscal year 2024. In Q1 2025 revenue was $0.
$34,443 as of October 8, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Cnbx Pharmaceuticals Inc. (CNBX), Medicus Pharma Ltd. (MDCX), Ocean Biomedical, Inc. (OCEA), Carisma Therapeutics, Inc. (CARM).